Forum für Wissenschaft, Industrie und Wirtschaft

Hauptsponsoren:     3M 
Datenbankrecherche:

 

Metabolic protein launches sugar feast that nurtures brain tumors

27.11.2012
PKM2 slips into nucleus to promote cancer; potential biomarker and drug approach discovered

Researchers at The University of Texas MD Anderson Cancer Center have tracked down a cancer-promoting protein's pathway into the cell nucleus and discovered how, once there, it fires up a glucose metabolism pathway on which brain tumors thrive.

They also found a vital spot along the protein's journey that can be attacked with a type of drug not yet deployed against glioblastoma multiforme, the most common and lethal form of brain cancer. Published online by Nature Cell Biology, the paper further illuminates the importance of pyruvate kinase M2 (PKM2) in cancer development and progression.

"PKM2 is very active during infancy, when you want rapid cell growth, and eventually it turns off. Tumor cells turn PKM2 back on - it's overexpressed in many types of cancer," said Zhimin Lu, M.D., Ph.D., the paper's senior author and an associate professor in MD Anderson's Department of Neuro-Oncology.

Lu and colleagues showed earlier this year that PKM2 in the nucleus also activates a variety of genes involved in cell division. The latest paper shows how it triggers aerobic glycolysis, processing glucose into energy, also known as the Warburg effect, upon which many types of solid tumors rely to survive and grow.

"PKM2 must get to the nucleus to activate genes involved in cell proliferation and the Warburg effect," Lu said. "If we can keep it out of the nucleus, we can block both of those cancer-promoting pathways. PKM2 could be an Achilles' heel for cancer."

By pinpointing the complicated steps necessary for PKM2 to penetrate the nucleus, Lu and colleagues found a potentially druggable target that could keep the protein locked in the cell's cytoplasm.

MEK, ERK emerge as targets

The process begins when the epidermal growth factor connects to its receptor on the cell surface. This leads to:

Activation of the MEK protein, which in turn activates ERK.
ERK sticking a phosphate group to a specific spot on PKM2.
Phosphorylation priming PKM2 for a series of steps that culminate in its binding to the protein importin, which lives up to its name by taking PKM2 through the nuclear membrane.

Once in the nucleus, the team showed that PKM2 activates two genes crucial to aerobic glycolysis and another that splices PKM RNA to make even more PKM2.

An experiment applying several kinase-inhibiting drugs to human glioblastoma cell lines showed that only a MEK/ERK inhibitor prevented EGF-induced smuggling of PKM2 into the nucleus. ERK activation then is mandatory for PKM2 to get into the nucleus.

"MEK/ERK inhibitors have not been tried yet in glioblastoma multiforme," Lu said. Phosporylated PKM2 is a potential biomarker to identify patients who are candidates for MEK/ERK inhibitors once those drugs are developed.

MEK inhibitor blocks tumor growth

The researchers also found that the two glycolysis genes activated by PKM2, called GLUT1 and LDHA, are required for glucose consumption and conversion of pyruvate to lactate, crucial factors in the Warburg Effect. Depleting PKM2 in tumor cell lines reduced glucose consumption and lactate production.

In mice, depleting PKM2 blocked the growth of brain tumors. Re-expressing the wild type protein caused tumors to grow. However, re-expression of a PKM2 mutant protein that lost its ability to get into the nucleus failed to promote tumor formation. Experiments in human glioblastoma cell lines showed the same effect.

Injecting the MEK inhibitor selumetinib into tumors inhibited tumor growth, reduced ERK phosphorylation, PKM2 expression and lactate production in mice. In 48 human tumor samples, the team found that activity of EGFR, ERK1/2 and PKM2 were strongly correlated.

Cause of PKM2 overexpression

Lu and colleagues also published a paper in Molecular Cell that revealed a mechanism for overexpression of PKM2 in glioblastoma. They found that EGF receptor activation turns on NF-?B, which leads to a series of events culminating in PKM2 gene activation.

PKM2 levels were measured in tumor samples from 55 glioblastoma patients treated with standard of care surgery, radiation and chemotherapy. The 20 with low PKM2 expression had a median survival of 34.5 months, compared to 13.6 months for the 35 patients with high levels of PKM2.

Level of PKM2 expression in 27 low-grade astrocytomas was about half of the expression found in higher grade glioblastomas.

"In these two papers, we show how PKM2 is overexpressed in tumors, how it gets into the nucleus, that nuclear entry is essential to tumor development, and identified potential drugs and a biomarker that could usefully treat people," Lu said.

Co-authors of the Nature Cell Biology paper are first author Weiwei Yang, Ph.D., Yanhua Zheng, Ph.D., Yan Xia, Ph.D., and Haitao Ji, Ph.D., of MD Anderson's Department of Neuro-Oncology and Brain Tumor Center; Xiaomin Chen, Ph.D., of MD Anderson's Department of Biochemistry and Molecular Biology; Ken Aldape, M.D., MD Anderson's Department of Pathology; Fang Guo, Ph.D., Nanomedicine Center, Shanghai Research Institute, China Academy of Science; Costas Lyssiotis, Ph.D., and Lewis Cantley, Ph.D., Beth Israel Deaconess Medical Center, Harvard Medical School.

This research was funded by grants from the National Institutes of Health (numbers 2RO1CA109035, RO1GM068566 and RO1GM56302), MD Anderson's Cancer Center Support Grant (CA16672) from the National Cancer Institute; and a research grant from the Cancer Prevention and Research Institute of Texas.

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world's most respected centers focused on cancer patient care, research, education and prevention. MD Anderson is one of only 41 comprehensive cancer centers designated by the National Cancer Institute. For nine of the past 11 years, including 2012, MD Anderson has ranked No. 1 in cancer care in "America's Best Hospitals," a survey published annually in U.S. News & World Report.

Scott Merville | EurekAlert!
Further information:
http://www.mdanderson.org

More articles from Health and Medicine:

nachricht New concept: Can Resuscitation be delayed?
31.03.2015 | Europäische Akademie Bozen - European Academy Bozen/Bolzano

nachricht For drivers with telescopic lenses, driving experience and training affect road test results
30.03.2015 | Wolters Kluwer Health

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Gemeinsam auf der Suche nach Wirkstoff gegen MRSA

Neues Projekt bündelt Kompetenzen des HZI und des Lead Discovery Center in Dortmund

Krankenhauskeime stellen in Deutschland ein immer größeres Problem dar. Der Grund: viele von ihnen sind resistent gegen die meisten herkömmlichen Antibiotika....

Im Focus: Rostocker Forscher entwickeln Mess-System für Schiffbau-Versuchsanstalten

Durch wissenschaftlich fundierte Daten der Forscher um Professor Nils Damaschke vom Institut für Allgemeine Elektrotechnik der Universität Rostock wird es künftig möglich, die Propellerform für Schiffe so zu optimieren, dass weniger Kraftstoff verbraucht und der Propellerverschleiß auf Grund von Kavitation reduziert werden kann. Die Wissenschaftler arbeiten inzwischen an der weiteren Verfeinerung eines kommerziellen Mess-Systems für die weltweit agierenden Schiffbau-Versuchsanstalten.

Kleinste Partikel spielen im täglichen Leben eine immer größere Rolle. Ob es sich um Schadstoffe in der Luft (Feinstaubbelastung) oder Zerstäubungsprozesse...

Im Focus: Den Synapsen bei der Arbeit zusehen

Göttinger Forscher beobachten Synapsenaktivität im Gehirn lebender Fruchtfliegen

Wissenschaftler der Universität Göttingen haben mit einer neuen Methode die Aktivität von Nervenzellen im Gehirn lebender Fruchtfliegen beobachtet. Bislang...

Im Focus: FiberLab-Roboter begeistert auf Photonics West in San Francisco

Mit ihrem „humanisierten“ Roboter zeigten Anna Lena Baumann und Wolfgang Schade erstmalig die erfolgreiche Umsetzung der 3D-Navigation über eine neuartige Lasermethode, der Standard Single-Mode-Glasfaser. Mehr als 17.000 Teilnehmer konnten den Roboter und FiberLab, das erste Projekt des Photonik Inkubators in Göttingen, auf der Photonics West in San Francisco kennen lernen.

Mit Hilfe eines in die Kleidung eingenähten Fasersensors wurden Armbewegungen eines Probanden dokumentiert und nach entsprechender Auswertung an den Roboter...

Im Focus: Femto Photonic Production: Neue Verfahren mit Ultrakurzpulslasern für die Fertigung von morgen

Für die deutsche Wirtschaft spielt die Lasertechnik eine herausragende Rolle: Etwa 40 Prozent der weltweit verkauften Strahlquellen und 20 Prozent der Lasersysteme für die Materialbearbeitung stammen aus Deutschland.

Beim Einsatz von Lasern in der Produktion sind deutsche Unternehmen führend. Diese Stärken gilt es zu erhalten und auszubauen. Deswegen hat das...

Alle Focus-News des Innovations-reports >>>

Anzeige

Anzeige

IHR
JOB & KARRIERE
SERVICE
im innovations-report
in Kooperation mit academics
Veranstaltungen

Premiere für die "innteract conference"

30.03.2015 | Veranstaltungen

Startup Weekend: In 54 Stunden von der Gründungsidee zur Firmengründung

30.03.2015 | Veranstaltungen

Große Bühne für Wissenschaft in drei Minuten

30.03.2015 | Veranstaltungen

 
B2B-VideoLinks
Weitere VideoLinks >>>
Aktuelle Beiträge

Clearstream eröffnet neues Büro in Zürich

31.03.2015 | Unternehmensmeldung

Einfluss von Materialporen beim Crash-Verhalten von Automobilbauteilen

31.03.2015 | HANNOVER MESSE

Ausschreibung Deutscher Journalistenpreis Neurologie 2015: Mensch im Blick – Gehirn im Fokus

31.03.2015 | Förderungen Preise